
- Pharmaceutical Executive-12-01-2010
- Volume 0
- Issue 0
Giddi Pharma: Putting the 'Special' into Specialty Pharma
How to achieve distribution diversification in a small market
"Sometimes being a distributor feels like being a babysitter," says Louis Chiang, president of Giddi Pharma. "You help a child to grow and then when it has grown up the parents get it back, and you have to find another baby to take care of. We know there will be a day when we have grown the child very well, and the parents will take it back, but we are very happy to see these children grow well and successfully. That's the reality, the fate of the distributor. All we can do is try to build a reputation for being a good babysitter."
Louis Chiang, President of Giddi Pharma
Giddi Pharma is a Taiwanese distributor whose main principals are specialty pharma companies such as Genzyme, for whom Giddi distributes 13 products in the Taiwanese market. Like many Taiwanese distributors, Giddi is looking to diversify its service offering in order to grow its business in a comparatively small market. Spotting the trend for an increasing number of drugs to be marketed towards self-pay markets due to the increased purchasing power of the Taiwanese population, and their desire to have access to the most innovative drugs on the market, Giddi has focused its attentions here: "The self-pay market is growing in Taiwan, and we have made sure not to miss this opportunity. We have seen that the industry is moving in that direction, because while the government continues to cap budgets and stick to reference prices, technology continues to grow and develop. A point will be reached where people want good products and are willing to pay the difference. This is why we wanted to incorporate these products into our product line."
Articles in this issue
almost 15 years ago
Taiwan: Pharma at the Tipping Pointalmost 15 years ago
Taiwan: Pharma at the Tipping Pointalmost 15 years ago
PharmEssentia: The 30-Year Dreamalmost 15 years ago
Patient Empowerment by Decision Making Literacyalmost 15 years ago
Taking Advantage of the Science Behind Marketingalmost 15 years ago
Gentle Collisions in Marketingalmost 15 years ago
Emerging Stakeholders with Clout: The Press Power Behind ProPublicaalmost 15 years ago
In Through the Out Dooralmost 15 years ago
US Anti-Corruption Regulation RisksNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.





